Kailera Q1 net loss $78.9M; advances obesity pipeline with Phase 3 start and positive data

Kailera Therapeutics, Inc.

Net loss of $78.9M in Q1 2026 vs $18.0M in Q1 2025; R&D expenses rose to $70.9M from $10.1M.
Cash $581.9M plus IPO proceeds of $718.8M expected to fund operations into mid-2028.
Initiated global Phase 3 KaiNETIC program for ribupatide injection; data expected 2028.
Positive Phase 2 oral ribupatide data: mean weight loss up to 12.1% at week 26; Phase 3 trials planned for early 2027.
Positive Phase 1 data for KAI-4729 tri-agonist: up to 16.0% weight loss at 12 weeks; Phase 1 outside China planned 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Kailera Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2026.

Period: the first quarter ended March 31, 2026
Result: reported results

Exact text from the filing

On May 26, 2026, Kailera Therapeutics, Inc. (the "Company") issued a press release reporting its financial results for the quarter ended March 31, 2026.

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

Kailera Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-239362

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.